News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment side-effects news

Show

From To
Hepatitis C treatment
Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe

“Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C

Published
19 April 2018
By
Michael Carter
Side-effects
Viral suppression protects against long-term liver damage caused by older HIV drugs

A history of treatment with some older antiretroviral drugs can have a lasting negative impact on liver health, German researchers report in PLOS One. They

Published
29 January 2018
By
Michael Carter
Hepatitis C treatment
Optimism About HCV Treatment Comes With Caveats

Despite significant advances in treatment for individuals with HCV infection, several important issues prevail in this patient population.

Published
22 March 2017
From
Medscape
Hepatitis C treatment side-effects
Are New Drugs for Hepatitis C Safe? A Report Raises Concerns

Drugs approved in recent years that can cure hepatitis C may have severe side effects, including liver failure, a new report suggests. The number of adverse events appears relatively small, and the findings are not conclusive. But experts said the report was a warning that should not be ignored.

Published
25 January 2017
From
New York Times
Hepatitis C treatment
HCV Drugs May Reactivate HBV, FDA Warns

Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

Published
06 October 2016
From
Medscape (free registration required)
Side-effects
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

Long-term therapy with the antiretroviral drug tenofovir increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published

Published
21 January 2016
By
Michael Carter
Hepatitis C treatment side-effects
Abacavir/lamivudine could be driving liver damage in ART-treated patients with HIV/HCV co-infection

Progression of liver fibrosis among ART-treated patients with HIV/HCV co-infection is associated with the type of nucleoside reverse transcriptase inhibitor (NRTI) “backbone”, Canadian research published in the online

Published
14 October 2015
By
Michael Carter
Hepatitis C treatment
Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy

Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone.

Published
29 June 2015
From
HIVandHepatitis.com
Hepatitis C treatment
Sustained response to treatment reduces fatigue in hepatitis C patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according

Published
06 May 2014
By
Liz Highleyman
Hepatitis C treatment
Merck combination suppresses HCV in mono-infected and co-infected patients

An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people

Published
21 March 2014
By
Liz Highleyman
← First12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.